Sevion Therapeutics Inc (SVON)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Sevion Therapeutics Inc (SVON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013606
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sevion Therapeutics Inc (Sevion), formerly Senesco Technologies, Inc. is a pharmaceutical company that discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company has developed protein nanocage system that allows delivery of nucleic acids and other payloads to target cells. Its product pipeline includes SVN-00, SVN-002, SVN-003, multiple GPCR targets and ion channel. The company’s SVN-002 is an antibody against an oncology target that has the potential to impact metastatic tumors, which include resistant to anti-VEGF treatments. Sevion is headquartered in San Diego, California, the US.

Sevion Therapeutics Inc (SVON) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sevion Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eloxx Pharma Raises Additional USD6 Million in Series C Financing 11
Partnerships 12
Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 12
Sevion Therapeutics to Form Joint Venture with Malvern Instruments 13
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 14
Sevion Therapeutics Enters into Research Agreement with Avidity NanoMedicines 15
Licensing Agreements 16
Fabrus Enters into Licensing Agreement with Scripps Research Institute 16
Equity Offering 17
Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 17
Senesco Raises USD3.5 Million in Private Placement of Shares upon Exercise of Warrants 18
Senesco Raises USD5.4 Million in First Tranche of Private Placement of Units 19
Senesco Technologies Completes Private Placement Of Shares For US$1.7 Million 20
Senesco Technologies Completes Private Placement Of Shares For US$1.25 Million 21
Senesco Technologies Completes Private Placement Of Shares For US$3 Million 22
Senesco Technologies Completes Second Tranche Of Private Placement Of Shares For US$1 Million 23
Senesco Technologies Completes Second Tranche Of Private Placement For US$1.65 Million 25
Acquisition 26
Sevion Therapeutics to Acquire Eloxx Pharma 26
Senesco Technologies Completes Acquisition of Fabrus 27
Sevion Therapeutics Inc – Key Competitors 28
Sevion Therapeutics Inc – Key Employees 29
Sevion Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Corporate Communications 31
Sep 26, 2017: Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer 31
Mar 10, 2016: Harlan Waksal, M.D. resigns as Chairman of the Board of Sevion Therapeutics 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sevion Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Sevion Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Eloxx Pharma Raises Additional USD6 Million in Series C Financing 11
Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 12
Sevion Therapeutics to Form Joint Venture with Malvern Instruments 13
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 14
Sevion Therapeutics Enters into Research Agreement with Avidity NanoMedicines 15
Fabrus Enters into Licensing Agreement with Scripps Research Institute 16
Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 17
Senesco Raises USD3.5 Million in Private Placement of Shares upon Exercise of Warrants 18
Senesco Raises USD5.4 Million in First Tranche of Private Placement of Units 19
Senesco Technologies Completes Private Placement Of Shares For US$1.7 Million 20
Senesco Technologies Completes Private Placement Of Shares For US$1.25 Million 21
Senesco Technologies Completes Private Placement Of Shares For US$3 Million 22
Senesco Technologies Completes Second Tranche Of Private Placement Of Shares For US$1 Million 23
Senesco Technologies Completes Second Tranche Of Private Placement For US$1.65 Million 25
Sevion Therapeutics to Acquire Eloxx Pharma 26
Senesco Technologies Completes Acquisition of Fabrus 27
Sevion Therapeutics Inc, Key Competitors 28
Sevion Therapeutics Inc, Key Employees 29
Sevion Therapeutics Inc, Subsidiaries 30

★海外企業調査レポート[Sevion Therapeutics Inc (SVON)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Protonex Technology Corporation:電力:M&Aディール及び事業提携情報
    Summary Protonex Technology Corporation (Protonex) is a fuel cell company, which carries out research, development and production of a wide range of power solutions. It principally offers advanced fuel cell power solutions for portable, remote and mobile applications. The company produces these prod …
  • Neovasc Inc (NVCN):医療機器:M&Aディール及び事業提携情報
    Summary Neovasc Inc (Neovasc) is a medical device manufacturing company that manufactures, develops, and sells cardiovascular disease products. The company’s products include Neovasc reducer, Neovasc tiara, and Neovasc tissue products. Its Neovasc tiara is a novel transcatheter device that is design …
  • Credit Suisse (UK) Private Banking:企業の戦略・SWOT・財務分析
    Credit Suisse (UK) Private Banking - Strategy, SWOT and Corporate Finance Report Summary Credit Suisse (UK) Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • TransAlta Corporation (TA):電力:M&Aディール及び事業提携情報
    Summary TransAlta Corporation (TransAlta) is an electricity generation company. It owns, operates and develops a divergent fleet of electricity generation assets. It generates electricity from a contracted portfolio of assets using diverse sources such as coal, natural gas, hydro, wind and geotherma …
  • XBiotech Inc (XBIT):企業の財務・戦略的SWOT分析
    Summary XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company offers monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed fo …
  • Extraction Oil & Gas Inc (XOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Extraction Oil & Gas Inc (Extraction Oil & Gas), formerly known as Extraction Oil & Gas LLC, is an independent upstream oil and gas company which focuses on the acquisition, development and production of oil, natural gas and natural gas liquids reserves in the Rocky Mountains. The company pr …
  • Chesapeake Energy Corp (CHK):石油・ガス:M&Aディール及び事業提携情報
    Summary Chesapeake Energy Corp (Chesapeake) is an upstream oil and gas company in the US. The company explores for, develops and produces oil and gas from its assets. It has liquid operations in Eagle Ford Shale; the Utica Shale; the Granite Wash, Cleveland, Tonkawa and Mississippian Lime plays in t …
  • VIA Technologies, Inc (2388):企業の財務・戦略的SWOT分析
    VIA Technologies, Inc (2388) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Accenture plc:企業の戦略・SWOT・財務情報
    Accenture plc - Strategy, SWOT and Corporate Finance Report Summary Accenture plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析
    Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Haitong Securities Co., Ltd.:企業の戦略・SWOT・財務情報
    Haitong Securities Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Haitong Securities Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Page Industries Ltd:企業の戦略・SWOT・財務分析
    Page Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Page Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Silence Therapeutics Plc (SLN):企業の財務・戦略的SWOT分析
    Summary Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc is a developer of therapeutics that channels gene silencing to cure disease. The company develops pipeline products such as Atu027 and Atu111. Its Atu027 is developed for the treatment of pancreatic, head and neck cancer …
  • A&D Company Ltd (7745):企業の財務・戦略的SWOT分析
    Summary A&D Company Ltd (A&D Company) is a medical equipment company that manufactures, designs, develops, and distributes advanced measuring, controlling, monitoring, and testing instruments. The company’s products include powertrain testing systems, digital analog converter, DSP platform, model ba …
  • Calumet Specialty Products Partners, L.P.:企業の戦略・SWOT・財務情報
    Calumet Specialty Products Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Calumet Specialty Products Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • PYCTX Ltd (PYC):企業の財務・戦略的SWOT分析
    Summary PYCTX Ltd (PYCTX), formerly Phylogica Ltd is a biotechnology company that develops intracellular biological therapeutics. The company utilizes proprietary phylomer peptide libraries and screening methodologies to identify unique peptide drug candidates. Its products include libraries and pep …
  • Punch Taverns Plc:企業のM&A・事業提携・投資動向
    Punch Taverns Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Punch Taverns Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Fair Isaac Corp (FICO):企業の財務・戦略的SWOT分析
    Fair Isaac Corp (FICO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Besso Insurance Group Limited:企業の戦略・SWOT・財務情報
    Besso Insurance Group Limited - Strategy, SWOT and Corporate Finance Report Summary Besso Insurance Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Uranium Energy Corp:企業の戦略・SWOT・財務分析
    Uranium Energy Corp - Strategy, SWOT and Corporate Finance Report Summary Uranium Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆